StockMarketWire.com - IXICO, the brain health company, has announced that Cygnus, a real world digital data collection study from people with cognitive impairment and dementia, has joined the high profile Dementias Platform UK (DPUK).

The four NHS Trusts participating in the project have now initiated enrolment in the mehealth digital technology platform which is being deployed for data collection and management. Consumer wearable devices containing accelerometers will also be deployed to collect information on sleep and activity. The Cygnus study aims to advance the development of digital healthcare in patients with cognitive impairment and dementia and their caregivers.

By joining Dementias Platform UK, Cygnus is now part of a high profile collaborative project that includes leading academic centres and pharmaceutical companies GSK, AstraZeneca and Johnson & Johnson. IXICO's mehealth platform is being used for data collection from participating services and patients and their caregivers. The mehealth® digital technology platform formed part of the Optimal Medicine acquisition in December 2015.

IXICO chief executive Professor Derek Hill said: "We believe digital technologies will improve the lives of both people with cognitive impairment and dementia and their families, potentially transforming how treatments are developed and delivered. The IXICO sponsored Cygnus project is now using such technologies in community memory services in the North of England. We are pleased our recently-acquired mehealth® platform is supporting this project in partnership with global pharmaceutical companies within the Dementias Platform UK."


At 8:10am: [LON:IXI] IXICO plc share price was 0p at 39.5p



Story provided by StockMarketWire.com